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OBJECTIVE — Islet autoimmunity has long been recognized in the pathogenesis of type 1
diabetesandisbecomingincreasinglyacknowledgedasacomponentinthepathogenesisoftype
2 diabetes. Islet reactive T cells and autoantibodies have been demonstrated in type 1 diabetes,
whereas islet autoimmunity in type 2 diabetes has been limited to islet autoantibodies. In this
study, we investigated whether islet reactive T cells might also be present in type 2 diabetic
patients and how islet reactive T cells correlate with -cell function.
RESEARCH DESIGN AND METHODS — Adult phenotypic type 2 diabetic patients
(n36)werescreenedforisletreactiveT-cellresponsesusingcellularimmunoblottingandﬁve
islet autoantibodies (islet cell antibody, GADA, insulin autoantibody, insulinoma-associated
protein-2 autoantibody, and zinc transporter autoantibody).
RESULTS — We identiﬁed four subgroups of adult phenotypic type 2 diabetic patients based
on their immunological status (Ab
T
,A b
T
,A b
T
, and Ab
T
). The Ab
T
 type 2
diabetic patients demonstrated T-cell responses similar to those of the Ab
T
 type 2 diabetic
patients. Data were adjusted for BMI, insulin resistance, and duration of diabetes. Signiﬁcant
differences (P  0.02) were observed among groups for fasting and glucagon-stimulated C-
peptideresponses.T-cellresponsestoisletproteinswerealsodemonstratedtoﬂuctuatelessthan
autoantibody responses.
CONCLUSIONS — We have identiﬁed a group of adult autoimmune phenotypic type 2
diabetic patients who are Ab
T
 and thus would not be detected using autoantibody testing
alone. We conclude that islet autoimmunity may be more prevalent in adult phenotypic type 2
diabetic patients than previously estimated.
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T
ype 1 diabetes results from cell-
mediated autoimmune -cell dys-
function and destruction, whereas
type 2 diabetes has been historically con-
sidered a metabolic disease (1). However,
increasing evidence is pointing toward a
relationshipamonginﬂammation,insulin
resistance, and the subsequent develop-
ment of type 2 diabetes. In fact, inﬂam-
mation in the pancreatic islets of type 2
diabetes includes the presence of cyto-
kines(2,3)andtheinﬁltrationofimmune
cells (3,4).
Despite the fact that the pathological
process in autoimmune diabetes involves
T cells, immune markers of autoimmune
diabetes have primarily centered on the
presence of circulating serum autoanti-
bodies to various islet antigens (5,6).
However, 20% of patients with newly
diagnosed autoimmune type 1 diabetes
are autoantibody negative (7). It was also
found that 9% of autoantibody-negative
type 1 diabetic patients carry the highest
risk HLA genotype (DR3-DQ2/DR4-
DQ8), strongly suggesting that these pa-
tients had autoimmune diabetes that was
undetected with autoantibody testing
alone (7). Furthermore, patients with ful-
minant type 1 diabetes have been re-
ported to be autoantibody negative but
demonstrate islet-speciﬁc T-cell re-
sponses (8). Therefore, we hypothesized
that there may exist a group of autoim-
mune phenotypic type 2 diabetic patients
who are autoantibody negative, similar to
the Ab
 type 1 diabetic patients, but who
demonstrate autoimmunity with islet re-
active T cells.
Over the years, we have been investi-
gatingislet-speciﬁcT-cellresponsesusing
cellular immunoblotting in diabetic pa-
tients (9–13). Our assay has been vali-
dated to have excellent speciﬁcity and
sensitivity for the detection of islet reac-
tive T cells in type 1 diabetic patients
(9,10). Moreover, we have previously ob-
served that T-cell reactivity to islet pro-
teins correlates more strongly with
impaired -cell function than with auto-
antibody positivity (12). In this study, we
used our validated T-cell assay for the de-
tection of islet reactive T cells to investi-
gate whether autoantibody-negative
T-cellreactiveadultphenotypictype2di-
abetic patients could be identiﬁed. We
provide evidence for the existence of this
group of autoimmune phenotypic type 2
diabetic patients. We conclude that islet
autoimmunity may be more prevalent in
adult phenotypic type 2 diabetic patients
than previously estimated and assessing
autoimmunity through T cells is of
importance.
RESEARCH DESIGN AND
METHODS— Inthisstudy,wewanted
to determine the autoimmune status of
patients aged 35–70 years with recently
diagnosed type 2 diabetes. We screened
patientswithin5yearsofdiagnosis.How-
ever, because diagnosis of type 2 diabetes
is often not as deﬁnitive a diagnosis as
type 1 diabetes, our inclusion criteria in-
cludedA1C8.0%,noinsulintreatment,
and use of only one oral diabetes medica-
tion to control glucose levels. The inclu-
sion criterion of A1C 8.0% was used to
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Department of Medicine, University of Washington, Seattle, Washington; the
2Department of
Medicine, DVA Puget Sound Health Care System, Seattle, Washington; the
3Seattle Institute for Biomed-
ical and Clinical Research, Seattle, Washington; the
4Diabetes Endocrinology Research Center, Seattle,
Washington; the
5Department of Medicine, Bronx-Lebanon Hospital Center, Albert Einstein College of
Medicine, Bronx, New York; the
6Department of Pediatrics, Division of Endocrinology, Cairo University,
Cairo, Egypt; and the
7Department of Pediatrics, T.C. Thompson Children’s Hospital, Chattanooga,
Tennessee.
Corresponding author: Barbara Brooks-Worrell, bbrooks@u.washington.edu.
Received 29 March 2010 and accepted 13 September 2010. Published ahead of print at http://care.
diabetesjournals.org on 20 September 2010. DOI: 10.2337/dc10-0579.
© 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Pathophysiology/Complications
ORIGINAL ARTICLE
168 DIABETES CARE, VOLUME 34, NUMBER 1, JANUARY 2011 care.diabetesjournals.orgensure that all patients were type 2 dia-
betic patients without “severe” disease
and thus not requiring insulin treatment.
Thesepatientswereeitherobeseorhadan
increased waist-to-hip ratio, had no his-
tory of ketonuria or ketoacidosis, and
were consecutively chosen from patients
meeting the criteria. Thirty-six pheno-
typic type 2 diabetic patients participated
in this study. Patients were evaluated for
T-cell responses, using cellular immuno-
blotting, and autoantibody responses to
islet proteins (islet cell antibody [ICA],
GADA, insulin autoantibody [IAA], insu-
linoma-associated protein-2 autoanti-
body [IA-2A], and zinc transporter
autoantibody [ZnT8A]). Written in-
formed consent was obtained from each
patient before sample collection. Patients
were subjected to blood draws on two or
three occasions 3 months apart. Patients
were classiﬁed as having autoimmune di-
abetes if two of two or two of three test
results were positive for any antibody or
T-cell assay or were classiﬁed as having
nonautoimmune diabetes if two of two or
two of three test results were negative.
Autoantibody assays
Assays for autoantibodies (ICA, GADA,
IAA, and IA-2A) were ﬁrst performed
(screeningassays)inSeattle,Washington,
and then were conﬁrmed in other labora-
tories(conﬁrmatoryassays).Allserumas-
says, both screening and conﬁrmatory,
were blinded when performed in the
laboratories.
Screening autoantibody assays
Screening autoantibody assays for IAA,
IA-2A, and GADA were performed at the
NorthwestLipid,Metabolism,andDiabe-
tes Research Laboratories at the Univer-
sity of Washington (Seattle, WA). ICA
assays were performed in our laboratory.
ZnT8AassayswereperformedbyDr.Lip-
ing Yu at the Barbara Davis Center (Den-
ver, CO).
GAD-65 autoantibody assay
GADAs were measured in a radiobinding
immunoassay on coded serum samples as
described previously (14). The levels of
GADA were expressed as a relative index
(GAD index) using one positive serum
(Juvenile Diabetes Foundation [JDF]
World Standard for ICA) and three nega-
tive standard sera from healthy subjects.
TheGADindexwascalculated,andapos-
itiveresultwassetat0.085,whichisthe
99thpercentilebasedon200normalcon-
trol subjects. Positive and negative con-
trols were run in duplicate in each assay.
In the Immunology of Diabetes Society
(IDS)–sponsored 2007 Diabetes Anti-
body Standardization Program (DASP)
workshop, the sensitivity of the GAD as-
say was 78% and speciﬁcity was 98%
(15).
IA-2A assay
Autoantibodies to IA-2 were measured
under conditions identical to those de-
scribedforGADAs(14)usingtheplasmid
containing the cDNA coding for the cyto-
plasmic portion of IA-2. The IA-2A index
for each sample was calculated using the
same JDF standard serum and control
serathatwereusedintheGADAassay.An
IA-2 index 0.017, the 99th percentile
based on 200 normal control subjects,
was the cutoff for positivity. In the IDS-
sponsored 2007 DASP workshop, the
sensitivity of the IA-2A assay was 64%
and speciﬁcity was 99% (15).
IAA assay
125I-Insulin was incubated with serum
and separation was achieved using a 50%
protein A/8% protein G-Sepharose mix-
ture. As with the other assays, positivity
was set at the 99th percentile of normal
control subjects. In the IDS-sponsored
2007 DASP workshop, the sensitivity of
theIAAassaywas16%andspeciﬁcitywas
99% (15).
ZnT8A assay
The presence of the zinc transporter au-
toantibody (16) was tested in serum from
thepatientsusingaradiobindingassayby
Dr.LipingYuattheBarbaraDavisCenter.
Cutoffvaluesweresetasthemean4SD
of the within-assay controls.
ICA assay
This assay was performed as described
previously (17). All sera with detectable
ICAwereendpointtitered.Thelowerde-
tection limit of our assay was 1 JDF unit
and the 95th percentile positivity thresh-
old was established at 6 JDF units based
on 4,000 normal school children (17).
Our laboratory had participated in a total
of eight Immunology of Diabetes Society
Workshops and IDS-sponsored proﬁ-
ciency programs for ICA with an average
sensitivity of 80% and speciﬁcity of
100%. In the IDS-sponsored Combined
Antibody Workshop, our ICA assay had a
speciﬁcity of 98% and a sensitivity of
76%.OurICAassayhadbeenvalidatedin
a serum exchange with the Diabetes Pre-
vention Trial–type 1 Diabetes (DPT-1)
ICA core laboratory. In this exchange, the
sensitivity of our assay was 85% with a
speciﬁcity of 100%.
Conﬁrmatory autoantibody testing
For conﬁrmation of autoantibody results,
autoantibody assays were performed for
ICAinthelaboratoryofDr.WilliamWin-
ter at the University of Florida (Gaines-
ville,FL)(18).AssaysforGADA,IAA,and
IA-2A were performed in the laboratory
of Drs. Liping Yu and George Eisenbarth
at the Barbara Davis Center (19).
ICA measurement
Conﬁrmatory ICA assays were performed
by the indirect immunoﬂuorescence
methodusingcryostat-cutfrozensections
of human blood type O pancreas. The re-
sults were expressed in JDF units, and a
value 10 JDF units was set as positive
(18).
GADA and IA-2A assays
Conﬁrmatory GADA and IA-2A assays
were performed by a combined radio-
binding assay as described previously
(19). The interassay coefﬁcients of varia-
tion(CVs)were10and5%forGADAand
IA-2A, respectively. The upper limits of
normal, nondiabetic sera were estab-
lished as the 99th percentile of 198
healthy control subjects. In the 2005
DASPworkshop,thesensitivityandspec-
iﬁcity were 76 and 99% for GADA and 64
and 100% for IA-2A, respectively.
IAAs
IAAs were measured by a microradiobind-
ing assay as described previously (20). The
interassay CV was 20% at low positive lev-
els. In the 2005 DASP workshop, the sensi-
tivityandspeciﬁcityformicro-IAAswere58
and 99%, respectively.
HLA haplotyping
HLA haplotyping was performed at the
University of Pittsburgh (Pittsburgh, PA)
by Dr. Massimo Trucco’s laboratory (21).
T-cell assay: cellular
immunoblotting
Cellularimmunoblottingwasperformedon
freshly isolated peripheral blood mononu-
clear cells to test for the presence of islet
reactive T cells (9–13). In brief, normal hu-
man islet cell preparations were subjected
to preparative one-dimensional 10% SDS-
PAGE and electroblotted onto nitrocellu-
lose. The nitrocellulose particles containing
isletproteinswereusedtostimulateperiph-
eralbloodmononuclearcellsfrompatients.
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T-cell proliferative responses to 4b l o t
sections. Human pancreatic islets were ob-
tained from the National Institutes of
Health (NIH)–supported Islet Cell Re-
source Centers. The speciﬁcity of the T-
cell responses from diabetic patients to
islet proteins has been demonstrated pre-
viously (11). We have participated in two
distinct NIH-supported T-cell validation
workshops designed to test the ability of
several different assays, including cellular
immunoblotting, to distinguish T-cell re-
sponses to islet proteins of type 1 diabetic
patients from those of control subjects
(9,10).Inbothworkshops,withtheuseof
masked specimens, cellular immunoblot-
tingdistinguishedtype1diabeticpatients
fromcontrolsubjectswithhighsensitivity
and speciﬁcity: 94 and 83% in the Im-
mune Tolerance Network (ITN) work-
shop and 74 and 88% in the Trial Net
workshop,respectively(9,10).Tocontrol
for interassay variation of the islet antigen
preparations, the quantity and quality of
islets are held constant among prepara-
tions, and new antigen preparations are
compared with and run alongside older
preparations.
Conﬁrmatory T-cell responses
Peripheral blood mononuclear cells were
analyzed for reactivity to 15 test antigens
as described previously (10). A response
was considered positive if reactivity was
positive to 4 antigens. Split samples
were available from 11 patients (3 in each
patient group except the Ab
T
 group
for which only 2 patient samples were
available) to be sent to Dr. Michael Dos-
ch’s laboratory (Hospital for Sick Chil-
dren, Toronto, ON, Canada). The T-cell
proliferationassayperformedbyDr.Dos-
ch’s laboratory was validated in the ITN-
supported study (9) with a sensitivity of
58% and a speciﬁcity of 94%. Responses
obtained from Dr. Dosch’s laboratory
conﬁrmed our data (results not shown).
C-peptide assays
Fasting and glucagon-stimulated C-
peptideresponseswereusedasameasure
of endogenous -cell function in all pa-
tients. Stimulated C-peptide was mea-
sured 6 min after the intravenous
injection of 1 mg glucagon. The C-
peptide assay is a two-site immunoenzy-
mometricassay,performedusingaTosoh
600 II autoanalyzer (Tosoh Bioscience,
South San Francisco, CA) at the North-
west Lipid, Metabolism, and Diabetes Re-
search Laboratories (12). The interassay
andintra-assayprecisionanalysisshowed
aC V10%. The assay has a sensitivity
level of 0.04 ng/ml.
Homeostasis model assessment of
insulin resistance
To estimate insulin resistance, the ho-
meostasis model assessment of insulin re-
sistance (HOMA-IR) was calculated from
fasting insulin (microunits per milliliter)
and fasting glucose (milligrams per deci-
liter) concentrations using the formula
(insulin  glucose)/405 according to
Matthews et al. (22).
Statistics
The nonparametric Mann-Whitney U test
was performed to determine statistical
signiﬁcance among the patient groups.
Multiple linear regression analysis was
used to estimate associations between
measures of C-peptide and antibody and
T-cell status while adjusting for BMI,
HOMA-IR, and duration of diabetes. Ad-
justed means were computed from these
models using Stata 10.1 (StataCorp, Col-
lege Station, TX). The Bonferroni correc-
tion was used to account for multiple
testing. P  0.02 was considered signiﬁ-
cantfordataadjustedforBMI,HOMA-IR,
and duration of diabetes.
RESULTS— Patients(n36)wereas-
sayed for their T-cell and autoantibody
responses and subsequently divided into
groups based on their islet autoimmune
status. The Ab
T
 patients were all male
Caucasians, whereas the other patient
groups were distributed among different
ethnicities. No women were found to be
Ab
T
, whereas the other groups were
closely split between men and women.
The only signiﬁcant difference (P  0.05)
in diabetes duration among the groups
was between the Ab
T
 group
(2.7 	 1.6 years) compared to the
Ab
T
 (1.0 	 0.7 years). Therefore, we
corrected the C-peptide data for disease
duration along with BMI and insulin re-
sistance. We screened patients two to
three times and were able to classify 75%
(27 of 36) of the patients using two blood
draws.Onlyninepatientsrequiredathird
blood draw for classiﬁcation. Of the pa-
tients requiring a third blood draw, six of
nine demonstrated ﬂuctuating autoanti-
body responses, whereas three patients
who were initially negative for T cells
demonstrated T-cell responses to islet an-
tigens during the second and third blood
draws. Low-titer ICA (10 JDF units) and
IA-2 were the autoantibodies demon-
strated to ﬂuctuate. The patient initially
identiﬁed as Ab
T
 who became Ab
T

wasobservedtobepositiveforIA-2atthe
second blood draw and GAD at the third
blood draw. After screening, 10 of the pa-
tients were determined to be negative for
bothisletautoantibodiesandisletreactive
T cells (Ab
T
), 15 were Ab
T
, 7 were
Ab
T
, and 4 were Ab
T
.
Conﬁrmatory autoantibody
responses
AllAb
T
andAb
T
patientswerecon-
ﬁrmed to be autoantibody-negative for
ICA, IAA, GAD, IA-2, and ZnT8A. The
Ab
T
 patients were limited to positivity
for either ICA alone (one patient) or IA-2
alone(twopatients)orIA-2withICA(one
patient). Three of the Ab
T
 patients
were positive for both GADA and ICA,
two patients were positive for ICA alone,
one patient was positive for GAD alone,
and one patient was positive for IA-2
alone. Conﬁrmatory autoantibody results
were consistent with screening results for
the samples tested.
T-cell reactivity to islet proteins
ThenumberofblotsstimulatorytoTcells
from the patients in each of the four
groups is shown in Fig. 1. There was no
signiﬁcant difference in the number of
blots stimulatory to T cells between the
Ab
T
 and Ab
T
 groups. T-cell re-
sponses to islet proteins from a subset of
patients in each group were conﬁrmed by
Dr. Michael Dosch’s laboratory (data not
shown).
-cell function
There were no signiﬁcant differences
among the patient groups in BMI, A1C, or
age of onset of diabetes (data not shown).
Mean data for C-peptide responses (fasting,
glucagon-stimulated, and C-peptide differ-
ence) were adjusted for BMI, HOMA-IR,
and duration of diabetes. Fasting C-peptide
was not calculated for the data adjusted for
HOMA-IR because the outcomes of fasting
C-peptide and HOMA-IR are going to be
highlycorrelatedasbothcalculationsreﬂect
insulin resistance. Results are shown in Ta-
ble 1. For fasting C-peptide, both the
Ab
T
 and Ab
T
 patients demonstrated
a signiﬁcantly lower response (P  0.02)
compared to the Ab
T
 patients when the
datawereadjustedforBMIanddiabetesdu-
ration.TheAb
T
patientsdemonstrateda
signiﬁcantly lower fasting C-peptide than
theAb
T
patientswhenthedataweread-
justedfordiseasedurationbutnotBMI.For
glucagon-stimulatedC-peptide,theAb
T

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T
 groups demonstrated signiﬁ-
cantly lower responses (P  0.02) com-
pared to both the Ab
T
 and Ab
T

groups when the data was adjusted for all
three variables. There were no differences
observed in fasting C-peptide or stimulated
C-peptide between the T
 (Ab
T
 and
Ab
T
)o rT
 (Ab
T
 and Ab
T
)
groups.
HLA genotyping
The DQB1 and DRB1 genotypes of the
patients were categorized as either “risk-
associated” if the HLA genotypes were
commonly associated with development
of type 1 diabetes (0201/0301, 0302/04,
or 0502/1601), “protective” if the HLA
genotypes were commonly associated
with protection from type 1 diabetes
(0602/1501 or 0303/0701), or “other”
(0501/X, 503/1401, or 0301/0401).
There were no signiﬁcant differences in
thepresenceofHLAgenotypesamongthe
groups of patients (data not shown).
CONCLUSIONS — In 2006–2007,
our group was investigating the relevance
of screening for autoantibodies versus is-
let reactive T cells to identify type 2 dia-
betic patients with varying degrees of
-cell function. We observed the poten-
tial existence of a group of phenotypic
type 2 diabetic patients negative for auto-
antibodies but positive for islet reactive T
cells(12).Atthattime,itwasdecidedthat
a study to investigate the potential exis-
tence of this new subgroup of type 2 dia-
betic patients (Ab
T
) along with their
demographic and -cell functional status
wasneeded.Thus,theresearchpresented
in this report was initiated. We recruited
other laboratories recognized for their ex-
pertise in assaying either autoantibodies
or T cells in diabetic patients for conﬁr-
mation of both our positive and negative
results. We observed that 11 of 36 (31%)
of the type 2 diabetic patients were Ab

with only 4 of 11 (36%) of the Ab
 pa-
tients being positive for GADA. If we had
deﬁned autoreactivity in this study as
GADA
 alone, we would have missed 22
of 26 (85%) of the autoimmune patients
because 0 of 4 Ab
T
 patients were
GADA
 and only 4 of 7 (57%) Ab
T

patients were GADA
. Our data demon-
strate that autoantibody reactivity may
also be more prevalent in type 2 diabetic
patients than reported previously if mul-
tiple autoantibodies are analyzed. One
importantissuetokeepinmindisthatthe
isletautoantibodieswescreenedforinour
study were autoantibodies that have been
identiﬁed as being important in type 1 dia-
betic patients. The autoantibody-negative
T-cell positive patients may have autoanti-
bodies that are as yet undeﬁned, which
couldraisethepercentageoftype2diabetic
patients exhibiting islet autoimmunity even
further. Therefore, based on our results, we
propose that there exists a subgroup of au-
toantibody-negative islet reactive T-cell–
positive adult phenotypic type 2 diabetic
patients (Ab
T
) who have diminished
-cell function similar to that in Ab
T

phenotypic type 2 diabetic patients.
T-cell assays assessing autoimmune
Figure 1—Number of blot sections stimulatory to T cells responding for each of the patient
categories.Thenumberofpositiveblotsectionsaredemonstratedonthey-axis.Patientgroupsare
shown on the x-axis. A positive response to 4–18 blot sections is similar to responses of type 1
diabetic patients (9).
Table 1—Mean C-peptide data for four subgroups of phenotypic type 2 diabetic patients
adjusted for BMI, HOMA-IR, and disease duration
Data adjustment
Patient groups
Ab
T
 Ab
T
 Ab
T
 Ab
T

n 10 4 15 7
BMI
Fasting C-peptide 3.9  1.45 5.8  1.38 3.1  1.39† 2.52  1.4†
Glucagon-stimulated
C-peptide 7.25  2.28 10.7  2.14 5.61  2.13*† 4.06  2.17*†
Change in C-peptide 3.34  1.3 4.91  1.24 2.51  1.24† 1.55  1.27*†
HOMA-IR
Fasting C-peptide ND ND ND ND
Glucagon-stimulated
C-peptide 6.71  1.93 9.99  1.80 5.98  1.86*† 4.46  1.83*†
Change in C-peptide 3.27  1.33† 4.6  1.22 2.61  1.24† 1.6  1.24*†
Diabetes duration
Fasting C-peptide 4.01  1.39 5.5  1.46 3.2  1.43† 2.35  1.40*†
Glucagon-stimulated
C-peptide 7.68  2.21 10.3  2.32 5.61  2.29*† 3.7  2.25*†
Change in C-peptide 3.6  1.3 4.72  1.36 2.48  1.36*† 1.35  1.30*†
Data are means 	 SD. ND, not determined. *P  0.02 compared with Ab
T
.† P  0.02 compared with
Ab
T
.
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perform and validate for use in diabetes
research. We were in a unique position to
use a T-cell assay (cellular immunoblot-
ting) that has been validated and con-
ﬁrmed to be able to detect islet reactive T
cells in type 1 diabetic patients (9,10)
with a sensitivity of 94 and 74% and a
speciﬁcity of 83 and 88% in two valida-
tion studies. In the validation study spon-
sored by Trial Net (10), the sensitivity of
any single autoantibody assay ranged
from 59 to 67%, whereas in the ITN-
sponsored validation study (9), the ad-
justed sensitivity for anti-GADA was 84%
and for ICA-512 was 58%. Therefore, the
sensitivity of the cellular immunoblotting
assay was comparable to the “gold stan-
dard” for detecting autoimmunity in dia-
betic patients, namely autoantibody
assays. We used cellular immunoblotting
to detect the presence of islet reactive T
cells in adult phenotypic type 2 diabetic
patients. Major drawbacks to using the
cellular immunoblotting assay for screen-
ing patients are the need for a large
amount of blood (30 ml) to perform the
assay and a source of human islets. We
are, however, working to optimize and
scaledowncellularimmunoblotting(23),
so that this technique may be more appli-
cable to future clinical trials. The exis-
tence of the Ab
T
 type 2 diabetic
patients is extremely important because
many larger studies, such as the UK Pro-
spective Diabetes Study (UKPDS), deﬁne
autoimmunity in type 2 diabetic subjects
based solely on autoantibody positivity
(24).Therefore,itisimportantthatfuture
studies of type 2 diabetes consider rede-
ﬁning islet autoimmunity to include islet
reactive T cells, thus potentially increas-
ing the percentage of type 2 diabetic pa-
tients exhibiting islet autoimmunity.
Autoantibody negativity in type 1 di-
abeteshasbeenlinkedtoincreasingageat
diagnosis of patients as well as increasing
timefromdiagnosis(7).Weobservedthat
the autoantibody responses seem to ﬂuc-
tuate more commonly than the islet reac-
tive T-cell responses. We also observed
the development of islet autoimmunity
(development of autoantibodies and/or T
cells) in a number of patients screened
twoorthreetimeswithinashortperiodof
time (3 months). This occurrence may
also add to the misclassiﬁcation of pa-
tients in studies if they are initiated using
only one screening result to classify
patients.
Comparing the C-peptide responses
among the patient groups, we observed
that fasting C-peptide was only different
betweentheAb
T
andAb
T
groupsif
the data were adjusted for diabetes dura-
tion but not BMI. In contrast, both the
Ab
T
 and Ab
T
 groups had a signiﬁ-
cantly lower fasting C-peptide response
comparedwiththatfortheAb
T
group.
For stimulated C-peptide, a signiﬁcantly
lower response was observed in both T

groups compared with the T
 groups
whenadjustedforBMI,insulinresistance,
anddiabetesduration.Thesedatasuggest
there are most likely differences among
the different groups, which could have an
inﬂuence on outcomes of clinical trials if
the patients are misclassiﬁed. Unfortu-
nately, this study was initiated to screen
onlypatientswithnewlydiagnosedtype2
diabetes to determine whether the
Ab
T
 patient population existed as a
substantial subpopulation of type 2 dia-
betic patients. The lack of longitudinal
follow-upinthisstudyprecludedusfrom
determining whether the presence of the
islet reactive T cells correlated with a de-
clinein-cellfunctionorwhetherthepa-
tients who were singularly positive for
either autoantibodies or T cells would be-
comepositiveforbothwithlong-termfol-
low-up. Although the sample size in our
study was sufﬁcient to identify the four
subgroups of type 2 diabetic patients, in
future studies to determine the preva-
lence of these subgroups a much larger
patient sample should be used. Based on
results published by Greenbaum et al.
(25), the mixed-meal tolerance test was
demonstrated to be superior to the gluca-
gon stimulation test and thus should re-
place the glucagon stimulation test for
future studies. However, the study out-
lined in this report was underway before
the results of the comparison of mixed-
meal tolerance test and glucagon-
stimulation tests were available (25).
As mentioned earlier, the prevalence
ofautoimmunityasdemonstratedbytest-
ing for multiple autoantibodies and islet
reactive T cells among adult phenotypic
type2diabeticpatientsisunknownatthis
time. Further studies investigating the
prevalence of autoimmunity in type 2 di-
abetic patients are needed. Our data sug-
gest that islet autoimmunity may be more
common than previously thought and
may be an important contributor to the
progressive decline in -cell function ob-
served in phenotypic type 2 diabetic pa-
tients. This is the ﬁrst study identifying a
group of phenotypic type 2 diabetic pa-
tients demonstrating autoimmunity to is-
let proteins without the presence of islet
autoantibodies.
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